Cervical Artery Dissection Clinical Trial
— TREAT-CADOfficial title:
Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
NCT number | NCT02046460 |
Other study ID # | 340/12 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | September 2013 |
Est. completion date | June 2019 |
Verified date | May 2024 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and complication measures. Methods: Randomized controlled, open labeled multicenter, non-inferiority trial with blinded assessment of outcome events. Primary endpoint: Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) - includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke*, new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.
Status | Completed |
Enrollment | 194 |
Est. completion date | June 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Acute ischemic or non-ischemic symptoms within 2 weeks 2. Verification of CAD-diagnosis (carotid and/or vertebral) by MR-techniques (at least one): - mural hematoma or - pseudo-aneurysm or - long filiform stenosis or - intimal flap or - double lumen or - occlusion situated more than 2 cm above the bifurcation of the carotid artery, revealing a pseudo aneurysm or a long filiform stenosis after recanalisation. 3. Written informed consent by patient or next-to-kin 4. 24h latency period in case of thrombolysis 5. Age > 18 years by time of inclusion Exclusion Criteria: 1. MR-contraindications (claustrophobia precluding MRI: patients agreeing to undergo MRI scanning with mild sedation may be entered into the study) 2. Contraindications to the use of anticoagulation (vitamin k antagonists, heparin) or ASA (according to the Swiss "Arzneimittelkompendium" http://www.compendium.ch/search/de or the "Rote Liste" (German centers) or "Lægemiddelstyrelsen - produktresume" for the Danish center (https://laegemiddelstyrelsen.dk/da/bivirkninger/find-medicin/produktresumeer/) and the judgment of the treating physician) 3. Pregnancy (Note: for women in child bearing age a pregnancy test has to be done prior to study entry) |
Country | Name | City | State |
---|---|---|---|
Denmark | University Hospital, Stroke Center Bispebjerg Hospital Copenhagen, Denmark | Copenhagen | |
Germany | University Hospital, Stroke Center Charite Berlin, Germany | Berlin | |
Germany | University Hospital, Stroke Center LMU Munich, Germany | Munich | |
Switzerland | Kantonsspital, Stroke Center Aarau, Switzerland | Aarau | |
Switzerland | University Hospital, Stroke Center Basel, Switzerland | Basel | |
Switzerland | University Hospital, Stroke Center Inselspital Berne, Switzerland | Berne | |
Switzerland | University Hospital, Stroke Center Geneva, Switzerland | Geneva | |
Switzerland | University Hospital, Stroke Center CHUV Lausanne, Switzerland | Lausanne | |
Switzerland | Kantonsspital, Stroke Center St. Gallen, Switzerland | St. Gallen | |
Switzerland | University Hospital, Stroke Center Zurich, Switzerland | Zurich |
Lead Sponsor | Collaborator |
---|---|
Stefan Engelter |
Denmark, Germany, Switzerland,
Engelter ST, Traenka C, Gensicke H, Schaedelin SA, Luft AR, Simonetti BG, Fischer U, Michel P, Sirimarco G, Kagi G, Vehoff J, Nedeltchev K, Kahles T, Kellert L, Rosenbaum S, von Rennenberg R, Sztajzel R, Leib SL, Jung S, Gralla J, Bruni N, Seiffge D, Feil K, Polymeris AA, Steiner L, Hamann J, Bonati LH, Brehm A, De Marchis GM, Peters N, Stippich C, Nolte CH, Christensen H, Wegener S, Psychogios MN, Arnold M, Lyrer P; TREAT-CAD investigators. Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial. Lancet Neurol. 2021 May;20(5):341-350. doi: 10.1016/S1474-4422(21)00044-2. Epub 2021 Mar 23. — View Citation
Traenka C, Gensicke H, Schaedelin S, Luft A, Arnold M, Michel P, Kagi G, Kahles T, Nolte CH, Kellert L, Rosenbaum S, Sztaizel R, Brehm A, Stippich C, Psychogios M, Lyrer P, Engelter ST; TREAT-CAD investigators. Biomarkers and antithrombotic treatment in cervical artery dissection - Design of the TREAT-CAD randomised trial. Eur Stroke J. 2020 Sep;5(3):309-319. doi: 10.1177/2396987320921151. Epub 2020 Jun 29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) - | CIHD - includes the following efficacy and safety outcome measures during the treatment period: includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke (including retinal infarction), new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death. | 3 months | |
Secondary | new ischemic strokes (including retinal infarction) | 3 months | ||
Secondary | new acute lesions on diffusion-weighted MRI | 3 months | ||
Secondary | any major extracranial hemorrhage | 3 months | ||
Secondary | any symptomatic intracranial hemorrhage | 3 months | ||
Secondary | any asymptomatic micro- or macrobleeds | 3 months | ||
Secondary | any death | 3 months | ||
Secondary | any increase in volume of the vessel wall hematoma at the followup cervical MRI as compared to the baseline MR-scan | 3 months | ||
Secondary | independence in activity of daily living (modified Rankin scale 0-2) at 3 months and at 6 months | 3 months | ||
Secondary | excellent functional outcome (modified Rankin scale 0,1) at 3 month and at 6 months | 3 months | ||
Secondary | any TIA (classical definition) | 3 months | ||
Secondary | recurrent cervical artery dissection | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01967511 -
Defining the Basis of Fibromuscular Dysplasia (FMD)
|
||
Completed |
NCT00238667 -
To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection
|
Phase 3 | |
Active, not recruiting |
NCT00657969 -
Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections
|
N/A | |
Recruiting |
NCT06258109 -
Risk of Recurrent CeAD After Pregnancy
|
||
Completed |
NCT04253535 -
Risk of Recurrence of Cervical Artery Dissection During Pregnancy and Puerperium
|